Quality of life and physical working capacity in pulmonary sarcoidosis

Objective To study the quality of life (QOL) and physical working capacity (PWC) in patients with pulmonary sarcoidosis. Materials and methods. Eighty patients with pulmonary sarcoidosis were examined (mean age 35 (39; 45) years), including 43 men (53.8 %) and 37 women (46.3 %). The duration of sarcoidosis was 3 (2; 4) years. Seventy-five percent of patients had pathologically proven sarcoidosis. All patients completed the SF-36 questionnaire; physical examination, chest computed tomography, spirometry and cardiopulmonary exercise testing (CPET) were conducted. PWC was determined according to the peak oxygen uptake (VO 2 peak) via CPET. Results. 29 (36,3%) patients had reduction of QOL (psychological and physical components of health). The most significant decrease of QOL was noted on the scale «general health» — 67 (47; 77) scores, «mental health» — 72 (54; 84) scores and «vitality» — 72.5 (50; 82.5) scores. Female patients (p=0.008) over 40 years of age (p=0.044) with clinically significant symptoms (p=0.012) and comorbidities (p=0.049) had a lower QOL. Patients with high or low QOL did not have differences in radiology stages, laboratory test results and lung function parameters. The female sex (OR 3.26, 95 % CI 1.15–9.23; p=0.026) and the clinical manifestations of sarcoidosis (OR 3.63, 95 % CI 1.06–15.47; p=0.041) were the independent factors of low QOL. Pulmonary sarcoidosis patients with exercise intolerance had the most significant reduction of the physical (p=0.037) and psychological components of health (p=0.033). Conclusion. Factors of QOL reduction in patients with sarcoidosis were female sex and clinically significant pulmonary sarcoidosis. In patients with low QOL, CPET can be used to determine the PWC and mechanisms of its reduction. The presented diagnostic algorithm will optimize the choice of therapy for patients with sarcoidosis.

pulmonary sarcoidosis, quality of life, physical exercise, cardiopulmonary exercise testing

1. Sarcoidosis. Clinical Guidelines. Moscow: RRO; 2019 [Electronic resource]. URL: http://spulmo.ru/obrazovatelnye-resursy/federalnyeklinicheskie-rekomendatsii/. (date of the application: 22.09.2019) [In Russian]

2. Chernikov А.Yu., Zemlyanskikh L.G. Life quality of patients with granulomatous respiratory lesions suffering from sarcoidosis and tuberculosis. Tuberculosis and Lung Diseases. 2016;94(12):48-52 [In Russian]. doi: 10.21292/2075-1230-2016-94-12-48-52. [In Russian]

3. Judson M.A. Quality of life in sarcoidosis. Seminars in respiratory and critical care medicine. 2017;38(4):546-58. doi: 10.1055/s0037-1602589.

4. Marcellis R., Lenssen A., Drent M. et al. Association between physical functions and quality of life in sarcoidosis. Sarcoidosis vasculitis and diffuse lung disease. 2014;31(2):117-28.

5. Marcellis R.G., Lenssen A.F., Elfferich M.D. et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J. 2011; 38: 628–34.

6. Pilzak K., Żebrowska A., Sikora M. et al. Physical functioning and symptoms of chronic fatigue in sarcoidosis patients. Adv Exp Med Biol. 2018; 1040: 13-21. doi: 10.1007/5584_2017_85.

7. Bahmer T., Watz H., Develaska M. et al. Physical activity and fatigue in patients with sarcoidosis. Respiration. 2018;95(1):18-26. doi: 10.1159/000481827.

8. Marcellis, R.G.J., Lenssen, A.F., De Vries G.J. et al. Is there an added value of cardiopulmonary exercise testing in sarcoidosis patients? Lung. 2013;191(1):43-52. doi:10.1007/s00408-012-9432-6.

9. Lopes A.J., Menezes S.L.S., Dias C.M. et al. Cardiopulmonary exercise testing variables as predictors of long-term outcome in thoracic sarcoidosis. Brazilian Journal of Medical and Biological Research. 2012;45(3):256-63. doi:10.1590/S0100-879X2012007500018.

10. Jastrzębski D., Ziora D., Lubecki M. et al. Fatigue in sarcoidosis and exercise tolerance, dyspnea, and quality of life. Adv Exp Med Biol. 2015; 833: 31-6. doi: 10.1007/5584_2014_18

11. Kostorz S., Jastrzębski D., Sikora M., et al. Predominance of Comorbidities in the Detriment of Daily Activity in Sarcoidosis Patients. Advs Exp. Medicine, Biology — Neuroscience and Respiration. 2018; 1040: 7-12. doi: 10.1007/5584_2017_87.

12. ATS/ACCP statement on cardiopulmonary exercise testing. American journal of respiratory and critical care medicine. 2003;167(2):211-77. doi:10.1164/rccm.167.2.211.

13. Ward S.A., Palange P. (ed.). Clinical Exercise Testing. European Respiratory Society. 2007;40(12):245 р. ISSN 1025-448x.

14. Gvozdenovic B.S., Mihailovic-Vucinic V., Ilic-Dudvarski A. et al. Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respiratory Medicine. 2008;102(11):1636-42. doi: 10.1016/j.rmed.2008.05.001.

15. Birnie D.H., Sauer W.H., Bogun F. et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014; 11(7):1305-23. doi: 10.1016/j.hrthm.2014.03.043.

16. Vizel I.Yu., Shmelev E.I., Vizel A.A. et al. Comparison of the young and elderly patients with newly revealed sarcoidosis. RMJ. 2018;10(I):16–20 [In Russian].

17. Bourbonnais J.M., Samavati L. Effect of gender on health-related quality of life in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(2):96-102.

18. Michielsen H.J., Peros-Golubicic T., Drent M. et al. Relationship between symptoms and quality of life in a sarcoidosis population. Respiration. 2007;74 (4):401-5.

19. Karadallı M.N., Boşnak-Güçlü M., Camcıoğlu B. et al. Effects of Inspiratory Muscle Training in Subjects with Sarcoidosis: A Randomized Controlled Clinical Trial. Respir Care. 2016;61(4):483-94. doi: 10.4187/respcare.04312.